Advertisement
Singapore markets closed
  • Straits Times Index

    3,287.75
    -5.38 (-0.16%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • Dow

    38,460.92
    -42.77 (-0.11%)
     
  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     
  • Bitcoin USD

    63,722.16
    -2,690.84 (-4.05%)
     
  • CMC Crypto 200

    1,349.75
    -32.82 (-2.37%)
     
  • FTSE 100

    8,088.18
    +47.80 (+0.59%)
     
  • Gold

    2,341.30
    +2.90 (+0.12%)
     
  • Crude Oil

    82.92
    +0.11 (+0.13%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     
  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     
  • FTSE Bursa Malaysia

    1,569.25
    -2.23 (-0.14%)
     
  • Jakarta Composite Index

    7,155.29
    -19.24 (-0.27%)
     
  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Merck’s Operating Expenditure and Recent Developments

Merck’s Operating Expenditure and Recent Developments

Merck’s (MRK) M&P (materials and production) expenses grew ~10% YoY (year-over-year) to $3.4 billion in the second quarter of 2018, while its M&A (marketing and administrative) expenses were flat YoY at $2.5 billion. The company’s R&D (research and development) expenses grew ~28% YoY to $2.3 billion from $1.8 billion, and its restricting expenditure grew 37% YoY to $228.0 million from $166.0 million. Analysts expect Merck to report non-GAAP M&P expenses of $2.7 billion in the third quarter, and non-GAAP R&D expenses of $2.0 billion.